The Biosimilar Hormones Industry Is Boosted By The Prevalence Of Growth/Metabolic Hormone Deficiencies

Biosimilar Hormones Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Biosimilar Hormones Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, July 1, 2021 / — The prevalence of deficiencies in growth hormones and metabolic hormones contributes to the market. The treatments required for hormone-related conditions are evolving over the years and the prevalence of hormonal deficiencies is generating higher demand for the hormone biosimilars market. For instance, according to the Italian Journal of Pediatrics, the prevalence of growth hormone deficiency (GHD) in childhood widely varies between 1 out of 3480 and 1 out of 30,000 children annually. In children, the growth hormone can influence bone mineralization and lead to several metabolic effects, including glucose and lipid homeostasis. Annually, about 6,000 adults are diagnosed with growth hormone (GH) deficiency in the USA. The growing need to treat patients with prevailing hormonal deficiencies drives the biosimilar hormones market.

The biosimilar hormones market consists of sales of biosimilar hormones by entities that engage in manufacturing biosimilar hormones. These hormones are used when patients have a drop in hormones in their bodies or are unbalanced. Only goods and services traded between entities or sold to end consumers are included.

Read More On The Global Biosimilar Hormones Market Report:

The global biosimilar hormones market is expected to grow from $1.94 billion in 2020 to $2.19 billion in 2021 at a compound annual growth rate (CAGR) of 12.9%. Biosimilar hormones market growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar hormones market is expected to reach $5.35 billion in 2025 at a CAGR of 25%.
Major players in the biosimilar hormones industry are Teva Pharmaceutical, Gedeon Richter, Intas Pharmaceuticals, Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, and GC Pharma.

The biosimilar hormones market covered in this report is segmented by type into teriparatide biosimilars, follitropin alfa biosimilars, insulin biosimilars, somatropin biosimilars, others, by application into research & biotechnology, diagnostics, biocatalysts, therapeutics, others, and by distribution channel into hospital and retail pharmacy, online pharmacy/epharmacy, specialty clinics.

Biosimilar Hormones Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides biosimilar hormones global market overview, forecast biosimilar hormones global market size and growth for the whole market, biosimilar hormones market segments, and geographies, biosimilar hormones global market trends, biosimilar hormones market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Biosimilar Hormones Market Report:

Here Is A List Of Similar Reports By The Business Research Company:
Biosimilar Growth Hormones Global Market Report 2021: COVID-19 Growth And Change To 2030

Drugs For Hormonal Replacement Therapy Global Market Report 2021: COVID-19 Impact And Recovery To 2030

Filgrastim Biosimilars Market – By Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Filgrastim Biosimilars Market Forecast To 2030

Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030

Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

Interested to know more about The Business Research Company?
Read more about us at

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

The Business Research Company
Follow us on LinkedIn:
Follow us on Twitter:
Check out our Blog:

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
Visit us on social media: